France breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 8.7% during the forecast period. The key factors that augmenting the market in this region include the prevalence of breast cancer, awareness program by the government and private organizations. Breast cancer is the most common cancer in women in this country. According to the WHO, about 56,162 new breast cancer cases and 13,353 mortalities estimated in 2018. Institute curie is a key centre for the treatment of breast cancer. The institute participating in more than 20 clinical trials for breast cancer on a variety of topics. The breast cancer screening program in France offers screening to women between 50 and 74 years of age which is covered by public health insurance.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/france-breast-cancer-therapeutics-market
France breast cancer therapeutics market is segmented on the basis of therapy. The therapy segment is further classified into chemotherapy, hormone therapy, targeted therapy, radiation therapy and others (surgery). Among all therapies, chemotherapy market held the largest market share in the France breast cancer therapeutics market. Chemotherapy is most used when cancer in the lymph nodes and irrespective of tumor size or menopausal status. Along with that it is used for the treatment of breast cancer in premenopausal women and referred for those women who diagnosed with early stage breast cancer for hormone receptor negative and HER2 positive cancer. The types of chemotherapy include adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy is used to destroy cancer cells that have been spread and not seen by the imaging tests. This method helps in reducing the cancer cells that form a new tumor in the other place of the body. Adjuvant chemotherapy reduces the risk of breast cancer coming back. Neoadjuvant chemotherapy can be used to reduce the size of the tumor, so it can be removed with less widespread surgery.
The companies which are contributing to the growth of the France breast cancer therapeutics market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Novartis International AG, F. Hoffmann-La Roche AG, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
A full report of France Breast Cancer Therapeutics Market available @ https://www.omrglobal.com/industry-reports/france-breast-cancer-therapeutics-market
France Breast Cancer Therapeutics Market Segmentation
By Therapy
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
- Radiation Therapy
- Others (Surgery)
Company Profiles
- AbbVie Inc.
- AstraZeneca PLC
- Astellas Pharma Inc.
- Bayer AG
- GlaxoSmithKline PLC
- Mylan NV
- Merck & Co., Inc.
- Novartis International AG
- Hoffmann-La Roche AG
- Sanofi S.A.
